How corporate involvement in psychedelic research could threaten public safety
By Elena Koning, PhD Candidate, Centre for Neuroscience Studies, Queen's University, Ontario
Elisa Brietzke, Professor, Department of Psychiatry, Queen's University, Ontario
Marco Solmi, Associate Professor Department of Psychiatry, L’Université d’Ottawa/University of Ottawa
Substantial economic growth in the psychedelic drugs market has drawn interest from corporations and start-ups. While this may accelerate research, it also sparks concerns about conflicts of interest.
Read complete article
© The Conversation
-
Monday, April 22, 2024